In addition to this, cardiac troponins have been increasingly studied in cancer patients before receiving oncological treatment: cTnI was found to be significantly higher in 25 anthracycline-naïve cancer patients (36.5 pg/ml; 95% confidence interval [CI], 25.1–47.9 pg/ml), as compared to 60 healthy controls (p < 0.01) (25), and in 25 patients with ovarian cancer prior to treatment, as compared to women with endometriosis or benign ovary masses (26). This evidence concerns the gene TNNI3 and cancer.